Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, international, multicenter, randomized, double-blind, placebo-controlled,
efficacy and safety study of ataluren in patients with nonsense mutation cystic fibrosis
(nmCF) not receiving chronic inhaled aminoglycosides.
Phase:
Phase 3
Details
Lead Sponsor:
PTC Therapeutics
Collaborators:
Cystic Fibrosis Foundation Cystic Fibrosis Foundation Therapeutics ECFS-Clinical Trial Network (ECFS-CTN) European Cystic Fibrosis Society-Clinical Trial Network (ECFS-CTN)